Meeting
2019 Genitourinary Cancers Symposium
Real-world PROCEED registry data: Sipuleucel-T in elderly men with metastatic castration-resistant prostate cancer (mCRPC).
Authors
Andrew J. Armstrong
Duke Cancer Institute and the Duke Prostate and Urologic Cancer Center, Durham, NC
Andrew J. Armstrong , Carl A Olsson , Ian D. Schnadig , Raoul S Concepcion , Jeffrey L. Vacirca , Ronald F Tutrone , Shaker R. Dakhil , Nancy N. Chang , Hong Tang , Bruce Brown , Nicholas J. Vogelzang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT01306890
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 177)
DOI
10.1200/JCO.2019.37.7_suppl.177
Abstract #
177
Poster Bd #
G20
Abstract Disclosures
Similar Posters
Poster
2019 Genitourinary Cancers Symposium
Experience with sipuleucel-T in metastatic castration-resistant prostate cancer (mCRPC) with visceral spread from PROCEED.
First Author: Nicholas J. Vogelzang
Poster
2016 Genitourinary Cancers Symposium
Analysis of the PROCEED registry by baseline prostate-specific antigen (PSA) quartiles: Preliminary analysis of real-world sipuleucel-T (sip-T) use.
First Author: Celestia S. Higano
Poster
2024 ASCO Genitourinary Cancers Symposium
Characteristics and outcomes of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177–PSMA-617 (PSMA-RLT) in a real-world setting.
First Author: David Kersting
Poster
2024 ASCO Genitourinary Cancers Symposium
Real world outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177-PSMA-vipivotide tetraxetan (Lu177-PVT).
First Author: Colin P Bergstrom